Author of 1 Presentation
SS 6.10 - Hounsfield unit-negative bowel filling agent in oncologic patients
Abstract
Purpose
To improve the detection of diseases arising from the intestinal mucosa, a Hounsfield unit (HU)-negative drinkable contrast was invented, and successfully tested in 25 healthy volunteers. After securing necessary allowances, a slightly modified HU-negative agent, Lu44, could be tested in severely ill oncologic patients without known bowel involvement.
Material and methods
Oncologic patients sent for abdominal CT were randomized so that 20 were administered equal volume of either Omnipaque 10%, or polyethylene glycol, and 40 Lu44. Examinations were anonymized. Small bowel luminal HU in 6-mm ROIs was independently read by two experts ignorant of patient’s medical history. Patients’ acceptance, adverse effects, extension and distension of filling agents were recorded.
Results
A half-time interim check was performed. In comparison, Lu44 revealed significant superiority in bowel wall-to-lumen contrast, high patients’ acceptance, and few adverse effects. Consequently, the series was terminated after 45 patients. Mean difference between bowel wall and lumen was 86HU for Omnipaque, 63HU for polyethyleneglycol, and 484HU for Lu44. No significant differences in extension and distension were noticed. Rank test showed no notable difference between the 2 investigators’ assessments. Image reading did not negatively influence.
Conclusion
Lu44 offers CT images with augmented bowel wall-to-lumen contrast, a prerequisite for improved diagnostics like T1-sequence images of MRI. Filling properties were not influenced by ongoing cancer treatments. Absence of side effects and high acceptance is important for these patients with severe symptoms. An ongoing series is testing Lu44 in patients with Crohn’s disease.
Video-on-demand
Author of 1 Presentation
SS 6.10 - Hounsfield unit-negative bowel filling agent in oncologic patients (ID 1057)
Abstract
Purpose
To improve the detection of diseases arising from the intestinal mucosa, a Hounsfield unit (HU)-negative drinkable contrast was invented, and successfully tested in 25 healthy volunteers. After securing necessary allowances, a slightly modified HU-negative agent, Lu44, could be tested in severely ill oncologic patients without known bowel involvement.
Material and methods
Oncologic patients sent for abdominal CT were randomized so that 20 were administered equal volume of either Omnipaque 10%, or polyethylene glycol, and 40 Lu44. Examinations were anonymized. Small bowel luminal HU in 6-mm ROIs was independently read by two experts ignorant of patient’s medical history. Patients’ acceptance, adverse effects, extension and distension of filling agents were recorded.
Results
A half-time interim check was performed. In comparison, Lu44 revealed significant superiority in bowel wall-to-lumen contrast, high patients’ acceptance, and few adverse effects. Consequently, the series was terminated after 45 patients. Mean difference between bowel wall and lumen was 86HU for Omnipaque, 63HU for polyethyleneglycol, and 484HU for Lu44. No significant differences in extension and distension were noticed. Rank test showed no notable difference between the 2 investigators’ assessments. Image reading did not negatively influence.
Conclusion
Lu44 offers CT images with augmented bowel wall-to-lumen contrast, a prerequisite for improved diagnostics like T1-sequence images of MRI. Filling properties were not influenced by ongoing cancer treatments. Absence of side effects and high acceptance is important for these patients with severe symptoms. An ongoing series is testing Lu44 in patients with Crohn’s disease.